Galectin Therapeutics (GALT) Misses Q3 EPS by 14c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.24), $0.14 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Rexford Industrial closes $1.2B portfolio sale to EQT Real Estate
• RBC bullish on Kraft Heinz, sees return to growth in 2027